Thanks @ACRheum for the opportunity to moderate a session on top abstracts in #myositis #ACR2024. Excited about the research on novel targets and future opportunities for my myositis patients @OhioStateRheum @TheMyositisAssc

Conditions that can be associated with hyper-inflammation/Cytokine Storm & DDx for iMCD [ldiopathic Multicentric Castlemans] including the mechanisms of cytokine storm in iMCD and treatment targets [Cytokine Storm Syndrome. R.Cron et al] #Rheumatology 👇📝

🧵 EULAR 2025 – Redefining lupus nephritis management 1️⃣ The 2025 EULAR recommendations for systemic lupus erythematosus with kidney involvement integrate 2019–2024 trial data and redefine LN as a systemic, precision-treatable phenotype rather than an isolated renal disease.

✨ IgG4-Related Disease: Emerging Insights One of the best #IgG4RD articles I’ve come across! Published in Allergy (2025) 🧾 🔹 4 Clinical Phenotypes Pancreato-biliary | Retroperitoneal/Aortitis | Head & Neck | Mikulicz/Systemic 🔹 Key Biomarkers Plasmablasts, galectin-3, CCL18

Flu season is on its way. 🤒🤧😷Hot tip 🔥: @ACRheum guidelines recommend holding MTX after flu vaccine for 2 weeks if disease activity allows. #OntarioBestPracticesResearchInitiative. @MovahediMoh @BindeeKuriya

#mskultrasound #gout #rhmsus

🚨 Cancer & IIMs: The Hidden Threat! 1/ Dermatomyositis = ⚡High-risk for malignancy. Year 1 post-diagnosis is the danger zone; most cancers show up within 3 years → Cancer-Associated Myositis (CAM). #MyositisAlert #IIM 2/ Risk by subtype: •DM → SIR up to 6.2 •PM → 1.75

🔥 Unlocking the mystery of axial PsA vs axSpA: Same family, different vibes! 🦴💥 Epidemiology: Axial PsA strikes 4-70% of PsA folks (older, more women); axSpA (0.2-1.4%) loves younger folks & HLA-B27. 🧬 Pathogenesis: Both share genes, but axial PsA’s HLA-B27 is less frequent

A 62 y/o woman with 3-year hx of RA & erosive OA treated with methotrexate presented with nail changes & discoloration, characterized by nail plates with black discoloration & increased transverse curvature involving all fingers nails with disappearance of the cuticle & lunula

Full read overview of Immune Checkpoint Inhibitors and their downside - immune related Adverse Events https://t.co/h1AzFaGVMz

Overview of the VEXAS Syndrome A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome. https://t.co/45qeSb14GB

Differential Diagnosis of Chondritis #EULAR2025 Think RP, Think GPA, Think VEXAS #Rheumatology #MedTwitter

Idiopathic inflammatory #myositis -#ILD treatment #EULAR2025

Good talk! Important slide.The monoclonal protein is usually a clue to the diagnosis 👇 #EULAR2025 #Rheumatology #MedTwitter

Castleman disease can be a diagnostic challenge, and more than half of multicentric CD cases are idiopathic. Expert perspective in Arthritis & Rheumatology examines types of idiopathic multicentric CD, their mimics, and current treatments https://t.co/3tIr4mrfgk

New content online: The pathogenesis, clinical presentations and treatment of monogenic systemic vasculitis https://t.co/xUa4e4EyQQ

💉 Good news for #SystemicSclerosis care: MSK corticosteroid injections appear safe in SSc patients with no increased risk of scleroderma renal crisis or serious complications. ✅ Careful monitoring still advised for early/high-risk cases. #SSc https://t.co/2ZiHu71rxz

Anti-synthetase syndrome (ASyS): Consensus on nomenclature and abbreviation for anti-synthetase syndrome is now done. Everyone should use this nomenclature and abbreviation for the ASyS going forward: an IMACS project

Dont forget to add in Omega-3 in your #Sjogrens patients with dry eyes.. #Rheumtology #MedTwitter #BSR25

Here is a wrap for the MSK ultrasound conference @OhioStateRheum @OSUWexMed 2 days of “joint”exploring and learning, with amazing faculty @JonathanDauMD @MymaAlbaydaMD #mskultrasound #ultrasoundconference #rheumatologyultrasoundconference

this week @OhioStateRheum outstanding speakers @MymaAlbaydaMD @JonathanDauMD